BRENNEN

Industries / Health / Pharmaceuticals / Contract drug manufacturing

Process development

Turning a drug company's laboratory recipe into a process that a plant can run the same way every time, at the scale and cost the medicine needs.

7

Milestones achieved, from 1998 to 2021.

1

To watch for: announced, not yet confirmed outside.

2

Open deliverables. Nobody has shipped them.

The road

AchievedWatch forOpen

Achieved

  1. 1998

    A new crystal form appears

    In the summer of 1998, supplies of Norvir, Abbott's HIV medicine sold as semi-solid capsules, were threatened when a new, much less soluble crystal form of its active ingredient, ritonavir, turned up. Abbott scientists later showed that this second form packs more stably and appeared suddenly in a highly concentrated solution, probably helped by a breakdown product.

    Lessona more stable crystal form that nobody has seen can still appear in production and change how a medicine behaves.

    ebi.ac.uk

    Credit

    John Bauer and colleagues, Abbott Laboratories

  2. 2004

    Measuring while the process runs

    The FDA issued guidance on process analytical technology (PAT), which it defines as "a system for designing, analyzing, and controlling manufacturing through timely measurements (i.e., during processing)" of the properties that decide quality. Companies could adopt it voluntarily under existing rules.

    fda.govfda.gov

    Credit

    US Food and Drug Administration

  3. 2006

    Quality designed in

    ICH Q8, the shared guideline on pharmaceutical development, took legal effect in the EU on 1 May 2006, and its 2009 revision set out Quality by Design (QbD): "a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control". A company can ask regulators to approve a design space, a proven range of inputs and settings; working inside it does not count as a change that needs approval.

    ema.europa.euema.europa.eu

    Credit

    ICH; European Medicines Agency (EMA)

  4. 2008

    One yardstick for waste

    Members of the ACS Green Chemistry Institute Pharmaceutical Roundtable, a group of drug makers convened by the American Chemical Society, held their first benchmarking of process mass intensity (PMI) in 2008: the mass of raw materials put in for each unit mass of active ingredient made. A 2011 paper set out why the group chose it, and the Roundtable now offers free PMI calculators, including ones for multi-branch routes and for predicting PMI early in development.

    acsgcipr.org

    Credit

    ACS GCI Pharmaceutical Roundtable; Concepción Jiménez-González, Celia Ponder, Quirinus Broxterman and Julie Manley (2011 paper)

  5. 2017

    Development and supply combined

    On 29 August 2017 Thermo Fisher Scientific, a maker of laboratory instruments and supplies, completed its purchase of Patheon, a contract development and manufacturing organization (CDMO), for about USD 7.2 billion. Patheon had fiscal 2016 revenue of about USD 1.9 billion, and Thermo Fisher said it would combine Patheon's work with its own clinical trial services and bioproduction products.

    biospace.com

    Credit

    Thermo Fisher Scientific; Patheon

  6. 2021

    Software outpaces chemists at tuning

    Chemists and computer scientists at Princeton University and process chemists at Bristol-Myers Squibb released open-source software (EDBO) that uses Bayesian optimization, a method that picks each next experiment from the results so far, to choose reaction conditions. In their test, an online game linked to real laboratory experiments, it beat expert chemists and engineers on the number of experiments needed and on consistency.

    ebi.ac.uk

    Credit

    Benjamin Shields, Abigail Doyle, Ryan Adams and colleagues; Bristol-Myers Squibb Chemical Process Development

  7. 2021

    Quality by Design, counted

    Judith ter Horst and colleagues at Zwiers Regulatory Consultancy read the public assessment reports of all 494 medicines the EU approved from 2014 to 2019. They found 151 (31%) were developed using QbD. Of the 271 full applications, 104 were, and that figure did not rise over the six years.

    Lessonan optional method spreads slowly; years after Q8, fewer than four in ten full applications used it.

    pmc.ncbi.nlm.nih.gov

    Credit

    Judith ter Horst, Sada Turimella and Frans Metsers

Watch for

  1. 20,000 reactions to train models

    Phlow, a CDMO in Richmond, Virginia, and Enveda, an AI drug-discovery company, say a joint pilot ran nearly 20,000 different chemical reactions in three months to train AI models that predict yield and purity. They say models trained on these data predicted better than models trained on public data alone, cutting development timelines "from years to months".

    Achieved whenthe data or a test on reactions the models have not seen is published, or an outside group reproduces the gain.

    pharmamanufacturing.com

    Claimed by

    Phlow and Enveda, January 2026

Open

  1. 01

    Route planners against plant routes

    A test set of approved, non-controlled small-molecule medicines for which both the first published route and the route used for commercial manufacture are public, for example in Organic Process Research & Development papers. Route-planning software proposes a route for each target, and each plan is scored on number of steps, whether its starting materials can be bought, estimated PMI and how close it comes to the commercial route.

    The brief
    Credit · unclaimed
  2. 02

    Quality by Design, per medicine

    A public table of every medicine the EU has approved since 2014, tagged from its public assessment report for QbD, design space, PAT and real-time release testing (releasing a batch on in-process data in place of final tests), with a link to the passage behind each tag.

    The brief
    Credit · unclaimed

Open 01 · the brief

Route planners against plant routes

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A test set of approved, non-controlled small-molecule medicines for which both the first published route and the route used for commercial manufacture are public, for example in Organic Process Research & Development papers. Route-planning software proposes a route for each target, and each plan is scored on number of steps, whether its starting materials can be bought, estimated PMI and how close it comes to the commercial route.

Why it is still open

Current benchmarks score plans against a single route taken from one patent. The authors of the RetroCast evaluation suite (December 2025) say this "rigidly" penalises shorter valid routes and that high "solvability" scores often fail to match known syntheses. I found no benchmark built on routes that plants actually run.

arxiv.orgarxiv.org

Built with what exists

AiZynthFinder (AstraZeneca, MIT licence) and ASKCOS, both open source; commercial planners such as Elsevier's Reaxys synthesis planning, which Lonza uses in its route-scouting service; the RetroCast scoring approach; the ACS GCI PMI calculators. An open-weight model such as Mistral Large 4 can be added as a further entrant; the note "A trillion open parameters" covers its release and licence.

pharmasource.global

  1. First step

    List 30 candidate medicines from published process chemistry papers and record, for each, the paper that gives its commercial route.

  2. Done looks like

    30 medicines, each with both routes cited, scores for at least four planners, and blind ratings by two process chemists, published with the code and the scoring sheet.

Open 02 · the brief

Quality by Design, per medicine

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A public table of every medicine the EU has approved since 2014, tagged from its public assessment report for QbD, design space, PAT and real-time release testing (releasing a batch on in-process data in place of final tests), with a link to the passage behind each tag.

Why it is still open

The 2014–2019 study reports totals by year and type of application; I found no per-medicine table in it, and its count stops in 2019.

pmc.ncbi.nlm.nih.gov

Built with what exists

EMA's downloadable medicine data tables, which it updates overnight; the assessment report PDFs; a language model to tag the quality sections, with a person checking every tag it is unsure of. An open-weight model such as Mistral Large 4 can run on a group's own servers (the note "A trillion open parameters").

ema.europa.eu

  1. First step

    Download EMA's medicine table, tag 50 reports for 2020 approvals by hand and use them as the answer key.

  2. Done looks like

    All EU approvals from 2014 to 2026 tagged; totals for 2014–2019 within 5% of the published study; at least 95% agreement with a hand check of 100 randomly chosen reports.